logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical closes C$305,000 non-brokered private placement financing

Net proceeds will be used to fund R&D programs as well as for general working capital

Jars of medical liquid
The company is seeking partners for the Sol-gel platform for delivery of cannabinoids

PreveCeutical Medical Inc (OTCMKTS:PRVCF) (CSE:PREV) announced Tuesday the closing of a C$305,000 non-brokered private placement financing.

The health-sciences company said in a statement that it plans to use net proceeds to fund research and development programs and as general working capital.

A total of 6.1 million units were issued at a price of C$0.05 per unit for gross proceeds of C$305,000. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one additional share at a price of C$0.08 per share for a period of 24 months, expiring February 11, 2021.

READ: PreveCeutical explores partnerships with pharma and biotech companies for co-development of Sol-Gel 

If the stock’s closing price is at least C$0.12 per share for a minimum of 10 consecutive trading days starting four months and one day after the closing of the financing, the company may accelerate the expiration of the warrants.

Shares fetched C$0.05 in Tuesday’s Canadian trading. They traded at US$0.04 on the OTC Markets.

The Vancouver-based company added that it has drawn down an additional C$205,000 from credit facilities. 

PreveCeutical’s work includes development of a dual gene therapy for curative and prevention therapies for diabetes and obesity and its Sol-gel platform for nose-to-brain delivery of medical compounds including cannabinoids.

Last month, the company said it plans to kick off exploratory discussions about potential partnerships with pharmaceutical and biotech companies to co-develop  Sol-Gel.

Contact Dennis Fitzgerald at [email protected]

Quick facts: PreveCeutical Medical Inc.

Price: 0.015 CAD

CSE:PREV
Market: CSE
Market Cap: $5.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PreveCeutical Medical making key advances with its Sol-gel program

Dr Harry Parekh, chief research officer for PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF), tells Proactive's Andrew Scott they've hit a number of key milestones with their Sol-gel program. He says they've now successfully optimised the conditions for extracting cannabinoids from one...

on 10/9/18

2 min read